From 1st March vets can sign up to be alerted to all recorded equine influenza cases in the UK, thanks to a new service from the Animal Health Trust (AHT) and Merial Animal Health.
Tell Tail is the UK's first equine influenza (EI) text alert service exclusively for equine vets, set up to provide practices and their clients with what could be invaluable information in the face of a potential outbreak.
Dr Emma Batson from Merial said: "Vets will be notified of an EI outbreak within 48 hours of confirmed diagnosis. Not only will this allow them to alert their clients, but we believe that it will also help to encourage horse owners to become more compliant with vaccination schedules.
"Currently it is estimated that only a third of the UK horse population is vaccinated for EI. This situation is not only a potential welfare issue, but it also provides practices with a significant opportunity to increase the number of horses protected against EI, resulting in a win-win situation for all."
Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT, believes the text alert service will also help improve awareness and knowledge of EI, and he hopes all equine vets will sign up for the scheme. He said: "We believe that the launch of the alert service for vets marks an important step in the quest to help minimise the risk of an EI outbreak in the UK.
"EI doesn't have a carrier state, which means that it never goes away and re-emerges, instead it circulates continuously. So without continued surveillance we could easily lose track of it.
"We hope that as well as allowing practices to track and respond to outbreaks in their area, the alerts will also encourage vets to send in samples from animals with cold and flu-like symptoms. This is a free service which in turn provides us with more information to circulate within the industry, allowing everyone to be more effective at managing the disease.
"Vaccination is our best defence against EI, but to remain effective the World Organisation for Animal Health (OIE) Expert Surveillance Panel, needs to make any update recommendations based on the latest position in the field. And this information can only be gathered via effective surveillance."
Dr Batson agrees and hopes that the combination of the Tell Tail text alert service and surveillance scheme will help to reduce the risk of an outbreak occurring in the UK. She said: "In the UK we continue to see regular confirmed outbreaks of EI, so we can never afford to become complacent about the risks.
"You only have to look at the relatively recent major outbreaks in Australia, South Africa, India and China, to see the devastating effects which can ripple throughout equine industries, both in financial as well as welfare terms."
Tell Tail is a free service. To register your interest, text your name, practice and postcode to 07797 801863. Alternatively, visit http://www.merial.com/ and click on the Tell Tail link, or speak to your Merial territory manager.
Zoetis has announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has approved Apoquel (oclacitinib tablet) in the European Union for the treatment of pruritus associated with allergic dermatitis and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age.
Developed by Zoetis, Apoquel is the first Janus kinase (JAK) inhibitor approved for veterinary use. The company says it inhibits the function of a variety of allergic, itch and pro-inflammatory cytokines dependent on JAK enzyme activity and thus stops the cycle of itch and inflammation occurring in skin allergies.
Michael Stegemann, Senior Director Global Development Organisation at Zoetis said: "Apoquel is a targeted treatment that specifically inhibits JAK-dependent cytokines involved in allergic skin disease in dogs. Its rapid anti-pruritic effect along with its anti-inflammatory properties provide fast relief to dogs. Relief from itch and inflammation is maintained in dogs receiving long-term treatment with Apoquel. This exciting innovation molecule offers quick, effective, and sustained itch relief; improves skin lesions continuously and can be used safely short or long-term."
Zoetis says that in clinical trials, Apoquel demonstrated safety and efficacy for the treatment of itch and resulted in improved skin lesions in dogs diagnosed with a number of allergic skin diseases as well as atopic dermatitis and treated either short or long term. The decrease in itch scores was observed by pet owners as soon as 24 hours after administration, the first observation time point, and itch continued to decrease compared to baseline until the end of the study. Skin lesions scores assessed by veterinary surgeons were significantly improved after one week and continued to improve long term during the studies (4 months). In these studies, the most common side effects observed in dogs treated with Apoquel were vomiting and diarrhea. Other reported side effects included lethargy, decreased or lack of appetite, skin irritation or infection, and ear irritation or infection.
Apoquel will be a POM-V treatment. Apoquel tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy if medium to long term treatment is required, such as in dogs with seasonal skin allergy and atopic dermatitis.
Zoetis plans to make Apoquel available to veterinary surgeons in the European Union during 2014. Meantime, Zoetis says it will be working with vets on the new science and research findings around itch and canine allergic diseases. For more information, visit www.zoetis.com, www.itchcycle.com.
Dechra Veterinary Products has launched Buprenodale, an opioid analgesic for cats, dogs and horses presented in a 10ml multi-dose vial.
Carol Morgan, Brand Manager said: "Following on from the introduction of Comfortan and Anesketin, our Buprenodale Multidose, 0.3 mg/ml solution for injection for dogs, cats and horses, is the latest addition to the portfolio.
"The active substance in Buprenodale is buprenorphine, the most commonly used opioid analgesic in small animal practice in the UK.
"Buprenodale Multidose joins a portfolio of Dechra products covering a wide range of species, different levels of analgesic efficacy and duration of action.
"The product is now available in a 10 ml multidose vial. It is suitable for post-operative analgesia in dogs and cats; post operative analgesia, in combination with sedation, in horses and potentiation of the sedative effects of centrally acting agents in the dog and horse."
For more information www.dechra.co.uk .
MSD Animal Health (Merck in the US and Canada), has launched Finadyne (flunixin), the NSAID for cattle, as a pour on.
According to the company, Finadyne Transdermal is the world's first non-parasiticide cattle product to be made available as a pour-on.
Dr. Martin Behr, technical manager at MSD Animal Health said: “Finadyne Transdermal is uniquely designed for rapid absorption into the bloodstream and its antipyretic effect has been demonstrated as early as two hours after treatment. This is because innovative penetration enhancers are included in the formulation to improve the absorption of the active ingredient flunixin through the skin.”
The new product comes in pre-calibrated packaging and uses a bottle designed for easy application along an animal’s back.
Dr. Behr added: “It’s much simpler for farmers to treat cattle in this way – as opposed to administering an injection, which can also mean needle-site lesions that can reduce the value of a carcass or compromise hide quality.
“The time taken to handle and treat animals will be much reduced with a transdermal NSAID. There will also be a saving on syringes and needles.”
Finadyne Transdermal (POM-V) is available now from veterinary wholesalers. Further information is available from the MSD Animal Health veterinary support group on 01908 685685.
The decision was made after Council heard increasing reports that practices have not been keeping records of POM-V parasiticide prescriptions within patient records as has always been required by the VMD.
This created a bit of a problem when the new 'under care' guidance came into force at the start of this month, which requires that veterinary surgeons must perform a physical examination as part of their initial clinical assessment of an animal before prescribing POM-V anti-parasitics.
Failing a record of an existing prescription, that would have meant re-examining large numbers of animals at a time when resources in the profession are already stretched.
RCVS President, Sue Paterson, said: “While it has been both surprising and disappointing to learn of such widespread non-compliance with legislation that has been in place for many years, Council decided to postpone the implementation of this one aspect of our new under care guidance to allow practices additional time to bring their prescribing protocols into line."
The delayed implementation date of 12 January 2024 relates only to the prescription of POM-V anti-parasitics.
The rest of the new under care guidance remains in effect from 1 September 2023
Ceva says the course is aimed at vets and nurses who want to build their confidence and take the lead in finding hypertension in cats in their clinic.
The course is hosted by Sarah Caney BVSc DSAM(Feline) MRCVS, one of the UK's leading specialists in feline medicine, and will cover things like finding out which cats need screening for feline hypertension, how to become confident in recommending a blood pressure check to owners, hints and tips on taking a reliable blood pressure measurement and handling cats calmly to reduce ‘situational hypertension’.
The course consists of four 30-minute recorded sessions including course notes and self-assessment questions for each module. Once completed, the delegate will receive a Hypertension Ambassador pin badge and a certificate for four hours’ CPD. The first 500 delegates to complete the course will be offered either a cat hide or an eye atlas.
The course can be completed online at any time. There are also weekly feline hypertension live sessions at 1pm, from Wednesday 4th March until Wednesday 25th March. They offer the opportunity for you to ask questions, but they're also recorded so you can watch them any time thereafter.
Suzanne Page BVSc MRCVS, cardio-nephrology-hypertension product manager at Ceva Animal Health, said: "Our HypertensionAmbassadors’ initiative will educate veterinary professionals on every aspect of feline hypertension to enable them to confidently talk to their clients about the condition, measure blood pressure in a cat-friendly way and offer advice on the different treatments available."
For more information, and to register, visit www.veterinarywebinars.com/feline-hypertension-ambassador.
However, when asked by VetSurgeon.org which audience - veterinary professionals, it's staff or the public - it was referring to, or what threats to safety and wellbeing were posed by X, the College refused point blank to answer.
So the real motivation remains unclear.
On the one hand, it could be a ridiculously over-sensitive move to protect its unknown audience from opinions that its staff find objectionable.
On the other hand, it could perfectly well be argued that short form social media reduces every discussion or debate to "I'm effing right and you're effing wrong", which is not appropriate for a scientific profession.
Equally, one could also argue that engaging in polarised debate online is not terribly good for one's wellbeing.
Or one could just argue that it's a terrible platform owned by a strangely meddlesome and interfering American.
However, given the College's strange refusal to expand on the reasons for its withdrawal, the first explanation seems more likely.
But who knows?
https://www.rcvs.org.uk/news-and-views/news/rcvs-statement-on-x-formerly-twitter/
The new voice skill offers three main features, a chocolate toxicity calculator for dogs, the nearest emergency vet finder, and answers to Vets Now's commonly asked pet health questions.
Head of clinical intelligence at Vets Now, Dave Leicester said: “With many people reluctant or not able to leave their homes due to the coronavirus pandemic, we're making veterinary advice accessible to everyone, through as many channels as possible including our website, video vet service, and now smart speakers.
"We fast-tracked our plans for the innovative voice skill in response to Covid-19 as we know how much pet owners are relying on remote veterinary advice just now — we’ve seen a huge spike in calls to our emergency contact centre and the uptake of our new video triage consultation service has been exceptional, with more than 500 video calls from worried pet owners since its launch in April.
"Our new voice skill is the next step in helping pets and their owners as much as we can during this incredibly difficult time. It’s a first release of the skill but we will continue to build and add advice to it in the weeks and months ahead.”
More information on the veterinary advice skill and how to access it can be found here www.vets-now.com/smart-speaker.
COMMENTI've just tried the new skill, and my first impression is that vets don't have to fear this is going to put them out of a job any time soon.
As with all things Alexa, there is a sporting chance she'll mishear what you said. But the bigger problem is that it may be a solution to a problem that doesn't exist.
I've had a dog for the last decade, and I could count the number of times I had a question for the vet that could be answered by an app on the fingers of one finger.
In fact, it was the time our dog ate chocolate.
But would I download a voice assistant just to answer the chocolate question?
No, I wouldn't.
Nor would I download a voice assistant to explain veterinary conditions, simply because I don't have questions of that nature more than once a decade. Who does? And if I wanted to know where the nearest emergency vet was, I'd either Google it or I'd ask Alexa herself (as opposed to summoning the Vets Now voice assistant specifically).
The sentiment behind this idea - making advice more accessible - seems sound, but I suspect that unless this assistant becomes truly encyclopaedic, it is never going to be useful enough to warrant installing on a smart speaker. Even then, one has to wonder whether the average pet owner has enough animal-related questions every month to warrant having an assistant to answer them.
The company announced last month that from 1st January next year, practices will have to order companion animal and ruminant products via either MWI or NVS (who will also fulfil the order), but will be invoiced direct by MSD.
Pig products will join aquaculture and poultry products to be supplied directly to customers by MSD Animal Health.
In its announcement, the company said that the new structure would allow the company to enhance the customer experience and more quickly adapt to changes in the market to better serve its customers.
VetSurgeon.org contacted the company for further clarification about how the customer experience would be improved.
The company explained that the two main benefits of the new structure concern price visibility and stock control.
A spokesperson for the company said: "Currently, customers may get a discount from us and separately a discount from wholesaler. With our new distribution model we will invoice monthly and all discounts will be on one invoice, so it will be easier to determine the actual price paid."
The spokesperson explained that with the old model, once stock was sold to wholesalers it would be allocated to customers, so there would be some held by MSD, some allocated and some in distribution: "The benefit of the new model is we will have full oversight of stock as it will be in our own warehouses or with distribution partners. If there are disruptions in the market, we will have better awareness of in market demand and we can allocate stock appropriately".
The company says the webinars will equip veterinary professionals with strategies to strengthen wellbeing both individually and for practice teams.
Lauren Hayes, Scientific and Regulatory Affairs Manager at Royal Canin, said: “Working within clinical veterinary practice can be hugely rewarding and enriching, but it cannot be ignored that our industry also has its challenges.
"Veterinary surgeons have a significantly higher risk of suicide compared to the general population and mental health issues around work life balance and compassion fatigue are widespread.
"Through our webinar series, we hope to encourage conversations around mental health and help provide advice directly from leading experts.”
The one-hour webinars will take place at 7pm every Wednesday throughout September.
https://vetportal.royalcanin.co.uk/news/new-veterinary-professional-health-webinar-series/
Belfast-based Des Thompson MRCVS was presented with the first ever RCVS Queen's Medal by Her Majesty at Buckingham Palace this afternoon.
Des, pictured right showing off the new medal with his wife Rosalie, received two separate nominations for the medal, both citing his decades of active involvement in veterinary politics which includes being president of the RCVS, the British Small Animal Veterinary Association (BSAVA), the Society of Practising Veterinary Surgeons (SPVS) and the Northern Ireland Veterinary Association, among other organisations.
Also cited was his willingness to help other members of the profession, particularly young vets at the beginning of their careers, through his involvement with organisations such as the Young Vet Network in Northern Ireland and the Veterinary Benevolent Fund.
The Queen's Medal was launched in 2013, with the approval of Her Majesty as Patron of the RCVS, and is now the highest award that can be bestowed upon a veterinary surgeon in recognition of a particularly outstanding contribution to the profession. In receiving the medal, Des was joined by Professor Stuart Reid, current RCVS President, Colonel Neil Smith, immediate past President, and Gordon Hockey, RCVS Registrar.
Des said: "It was a complete honour and a wonderful experience to be received by Her Majesty at Buckingham Palace today, and I'm thrilled to have been awarded the RCVS Queen's Medal. Her Majesty was interested to hear about Northern Ireland, and the fact that I've been practising there since I qualified."
Pooch & Mutt has 20x 40-day trials of its new joint & bone supplement, Mobile Bones Concentrate, to give away to veterinary professionals.
Guy Blaskey from Pooch & Mutt said: "At The London Vet Show vets and vet nurses told us that they loved the new Mobile Bones Concentrate because at just £9.99 per month it costs less than other joint supplements (whilst having the same high quality ingredients), it takes up a very small amount of shelf space and it doesn't involve the client having to either change their dog's food or stuff pills down their dog's throat."
In response to requests from vets and vet nurses to try the new joint supplement, Pooch & Mutt have set up a dedicated website at www.jointsupplementfordogs.com where you can apply from one of twenty 40 day trials.
Guy continued, "We did not want to simply send samples out to everyone. By setting up the site we can choose a variety of dogs from different breed and with different conditions to send a full 40-day trial to. We hope to get regular feedback from the vets, vet nurses and dog owners involved in the trial and publish it on http://www.jointsupplementfordogs.com/ for everyone else to see."
The trials are available to all veterinary professionals and can be for their own dogs, or dogs belonging to their clients.
The group is hoping to raise more than £5,000 for the hospital by donating £1 for every pet vaccinated at its West Derby, Gateacre, St Helens and Widnes practices over the next four months.
Sarah Kirkman MRCVS, from White Cross Vets in Gateacre, said: "It’s our job to care for pets, but we also really care about the communities in which we operate, and we have a real affinity with the hospital. This partnership means we’re protecting pets, by vaccinating them against a wide range of nasty diseases, as well as raising money to support the invaluable work that the hospital does."
Allan Eves from Alder Hey Children’s Charity said: "We care for over 275,000 children, young people and their families treating everything from common illnesses to highly complex and specialist conditions. We also lead research into children’s medicines, infection, inflammation and oncology and our charity has raised over £22m to support Alder Hey Children’s Hospital, funding life-saving medical equipment, research and vital facilities. We are so pleased to be working with White Cross Vets on this superb fund-raising initiative and can’t wait to meet the vets and nurses who are helping us."
Sarah added: "We are aiming to raise £5,000, but it could be more. We also want to support the hospital’s therapy dog by providing them with our Complete Wellness Plan for free. The plan provides free health-checks, veterinary care and preventative treatment on an ongoing basis. We already give free membership to several Fire Service Search Dog Teams, as we feel it’s really important to look after these amazing dogs which dedicate their lives to help people."
The charitable campaign is running from the 4th September until the 31st December and plans are also in place for the veterinary surgeons and nurses from White Cross Vets to visit the hospital regularly to talk to the children about pets.
Sarah said: "We give every one of our team four paid donation days a year, so that they can volunteer with a charity of their choice, and we are keen to further our partnership with the hospital by visiting regularly. We already do this in numerous schools across the region and know just how much children love to find out about our day to day roles, and they always have plenty of interesting questions for our nurses and vets to answer."
The £11m project, which is backed by Mars Petcare, will include a cutting-edge imaging suite, state-of-the-art treatment facilities and a new linear accelerator.
Plans also include separate cat and dog waiting areas and client walking and comfort areas, seven operating theatres, 15 consultation rooms, recovery suites, lecture halls, a dedicated ICU department and plans for a future hydrotherapy suite.
Daniel Hogan, operations manager at Southfields (pictured right), said: "This is a really exciting time for Southfields and our relocation will provide the region with one of the largest and best-equipped veterinary centres in the UK.
"The team and expertise have grown significantly in the past 18 months. We are very excited to continue to expand the unique and innovative offerings in patient care at our centre.
"Increasing in size will also enable us to provide a dedicated staff wellbeing area and an education centre and lecture hall, which will offer some very exciting qualifications and courses for the wider profession.
"Since our rebranding in 2017, we pride ourselves on leading the industry as a truly multidisciplinary centre with specialists from across the globe, including one of the most illustrious oncology teams in the country. Once this new site is launched, we will be able to offer an even more comprehensive service to our clients and patients."
For more information about Southfields, visit www.southfields.co.uk.
The company has launched a ‘Vet Show CPD hub’ (www.myelanco.co.uk/brand/lvshub) which, as the name suggests, hosts a variety of CPD presentations accompanied by competitions, including one in which you can win £250 Amazon vouchers.
The CPD hub also has information about the company's range of products, including Credelio, Neptra, Galliprant and Advocate.
From the 10th November, Elanco will also host a series of webinars in partnership with the London Vet Show (https://london.vetshow.com/elanco):
As a thank you, the first people to sign up to the webinars will also get an ‘Elanco Vet Show CPD at home’ box, with goodies to enjoy while tuning into the virtual event.
Tina Hunt, managing director of Elanco UK/Ireland, said: "2020 has been a year of incredible change, which has included our global acquisition of Bayer Animal Health. While we remain physically separated, it is important to us that we continue to engage with our veterinary friends and customers to maintain the sense of community that networking events can be so vital in nurturing.
"We also wanted to take this opportunity to recognise the commitment of veterinary professionals across the UK and thank you for your ongoing support and dedication at the forefront of animal care. Our entire team look forward to you joining us for three exciting webinars and to hosting you on our hub."
For the trial, the company has partnered with Pennard Vets in Kent, where they're using Google Glass to transmit what the practitioner sees straight to the consulting experts at VetCT.
The remote VetCT specialist is able to view and remotely record, zoom, adjust lighting, annotate and send images back for the wearer of the glasses to view.
They are also able to discuss the case live with team in the clinic.
As part of the trial, images streamed via the glasses are being compared against those shot on a higher resolution mobile phone.
Director and Innovation Lead at VetCT, Julien Labruyère said: “We have a tremendous resource of specialist knowledge and expertise within our global team, and are exploring new ways to maximise the potential benefits of real-time clinical mentoring, teaching and case support.
"This first step we have taken with Google Glass marks the start of an exciting journey to make smart glasses technology useful to help vets in practice."
Caroline Collins, Director at Pennard Vets, said: “Trialling the glasses has been a fascinating exercise. We’re now looking at cases where we could see the most benefit from real-time specialist feedback and hands-free capability. It could be a real game-changer in some situations, for example with remote guidance of patient examinations or complex procedures.”
To learn more about VetCT visit www.vet-ct.com.
In common with the various other telemedicine platforms which have come to market in recent months, the app will allow veterinary professionals to give help and advice to clients and maintain a revenue stream whilst maintaining social distancing.
VisioCare is highlighting a number of features over and above standard video conferencing, including the ability for the clinician to take photos, video and produce a case file that can be added to the clinical record. The system also allows vets to access the client's smartphone and zoom into areas that need to be examined or turn on a flashlight to improve visibility.
Visiocare says it has also been able to address limitations in clarity due to poor smartphone reception.
Linkyvet includes a payment module - which will be integrated free of charge for orders taken during April - so practices can charge for services provided remotely.
Alexander Arpino, Managing Director of Veterinary Insights, said: "During the current COVID-19 situation, Linkyvet has real potential for triage, as well as enabling routine consultations, without putting anyone at risk. It's good news for patient care, staff wellbeing and also ensuring that the practice remains a viable business that's still there for everyone to return to when life returns to normality.
"Outside crisis times, the tool has ongoing value, providing a great way to generate revenue from services such as advisory consultations and follow ups provided remotely and giving clients a convenient alternative to visiting the practice."
VisioCare Linkyvet is available as a standalone tool or can be included in a bundle with other VisioCare products such as VisioCare Consult, which provides explanatory animations and videos that support clinician recommendations and the myBuddy app, which provides a secure and personalised communication channel between clinic and pet owner.
For more information, visit www.visiocareservices.com or contact your VisioCare Business Development Manager: telephone 01403 800135 or email enquiries@visiocareservices.com.
The kit contains the ergonomically designed Henke-Sass Wolf injector with an adjustable dose selector, five single piece Intranasal RSP nozzles – with ‘luer’ lock attachment, which supports easier removal, cleaning and/or replacement – and instructions for use.
For more information, contact your local MSD Animal Health account manager.
In mid-September, the Association wrote to the RCVS expressing concern about the August extension to the temporary guidance.
In the latest update from the RCVS, the temporary measure has now been extended to 31 October but the flowchart and guidance have been updated to add some additional steps before a POM-V product can be prescribed remotely.
The BVA says that while it supported the original decision in March as a pragmatic solution and direct response to government restrictions surrounding Covid-19, it is now questioning the ongoing need for such a relaxation in the rules.
In the letter to the RCVS, the BVA also asked for a timeframe for the publication of the results of the RCVS survey of practices’ experiences of remote consulting and prescribing. The Association's own under care working group, chaired by Nigel Gibbens, has been developing a position to respond to the RCVS review.
BVA President James Russell (pictured right) said: "We understand that allowing remote prescription of POM-Vs was a necessary measure at the height of the lockdown, as practices struggled to assess patients in person.
"However, the veterinary professions have done a fantastic job in adapting to the restrictions and are now able to work safely and see patients.
"Whilst we recognise the RCVS has provided additional guidance for the remote prescribing of POM-V, we cannot currently see any reason why a new client would be unable to access in-person veterinary care in the first instance and we are asking RCVS Council to reconsider this measure when it meets in Oct.
"It makes sense to continue allowing vets to remotely prescribe for existing patients, for example if an owner is shielding, but we feel it is no longer appropriate to be remotely prescribing to animals that have never been physically examined by the vet.
“The question of whether we should be able to remotely prescribe POM-V products without first seeing an animal is an important and live debate, and we welcome the resumption of the College’s review. But the longer that temporary measures are in place, the greater the expectation from animal owners that they will always be in place, and the harder it will be to have the discussion about the best way forward.
“As a profession, we are rightly concerned about antimicrobial resistance and we pride ourselves on the responsible use of medicines. Continually extending the temporary measures without a full analysis would risk undermining our position.”
Merck and sanofi-aventis, owners of Merial and Intervet Schering-Plough respectively, have announced that they will not be combining the two animal health businesses as had been planned since March 2010.
In a joint announcement today, the companies said they are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. The companies agreed that ending their plan is in the best interests of both companies and their respective shareholders, as well as the employees of Merial and Intervet/Schering Plough.
Sanofi-aventis says it remains strongly committed to its animal health activities, which it will continue to develop under the Merial brand as a growth platform of its diversified health business. Merial is one of the world's leading innovation-driven animal healthcare companies dedicated to research, development, manufacturing and commercialization of veterinary pharmaceuticals and vaccines, that generated annual sales of US $ 2.6 billion in 2010.
Merck has also stated its commitment to animal health and Intervet/Schering-Plough, a global leader in the research, development, manufacturing and sale of veterinary medicines which generated sales of US $ 2.9 billion in 2010
As a result of termination, both Merial and Intervet/Schering-Plough will continue to operate independently.
An online presentation by Danielle Gunn-Moore, Professor of Feline Medicine at the Royal (Dick) School of Veterinary Studies in Edinburgh, has been launched by Dechra Veterinary Products as part of its Dechra Academy training suite.
During the presentation, Professor Gunn-Moore uses a case study approach to discuss all aspects of the condition from diagnosis through to its treatment, management and on-going monitoring. She reminds viewers that an individual approach must be taken in treating affected cats as the clinical signs can be subtle and starting treatment with the lowest possible dose of anti-thyroid medication is likely to prove physiologically beneficial.
"The study I've recently been involved in showed that the treatment of hyperthyroid cats can result in iatrogenic hypothyroidism*. Hypothyroid cats are significantly more likely to develop azotaemia than euthyroid cats - and hypothyroid cats that developed azotaemia in the study had significantly shorter survival times*.
"The message for practitioners is that there is no 'standard recipe' in treating hyperthyroidism. The clinical signs aren't always obvious and it's important to check for concurrent heart and kidney disease. You then need to tailor treatment, starting with a low dose of medication and, if necessary, increasing it by the smallest increments possible."
To watch Professor Gunn-Moore's presentation, visit www.dechra.co.uk/hyperthyroidism.
Reference:* Williams, T. et al (2010) JVIM 24: 1086-1092
All vets are encouraged to take part, and everyone who does will get a copy of the results.
The survey covers small animal, large animal and equine in all aspects of preventative health care and surgery.
It also looks at repeat prescription charges, the routine use of analgesia and antibiotics in neutering and lab interpretation fees, comparing them to last year.
https://surveys.spvs.org.uk
The majority of posters, leaflets and other displays in veterinary practice waiting rooms are more effective at building ambience than increasing the turnover of the practice or selling a particular product or brand, according to a new survey carried out by veterinary marketing agency TMA.
The national survey of more than 100 veterinary practice managers found that:
TMA says it believes practices are missing out on a major marketing opportunity by not changing their displays more often, not being more selective about what is displayed, and not making the most of interactive or digital display technology.
Helen Cawthra, Managing Director of TMA believes that product manufacturers are also missing out on a major opportunity. Significantly less than half of all display and point-of-sale material in vets' waiting rooms is provided by suppliers. On average, 64% is sourced by the veterinary surgeons themselves.
Helen said: "Two thirds of respondents claim that they hardly get any materials from suppliers. The same number claim they would be more likely to put up more if they were provided with it.
"It is all very well building ambience and providing loyalty but in today's market, it is important that vets take hold of every opportunity to generate revenue in every way possible. Vets and the manufacturers are both missing out."
The final deadline for paying the fee was 31 May 2019, with the 346 who did not pay being removed on 1 June 2019, compared to 308 last year.
Those who were removed from the Register but have subsequently paid to be restored are not named on the list.
The RCVS says it sent reminders to all MsRCVS, including emails and text messages, reminding them that the fee was due. Letters were sent to those members that the College does not have an email address or mobile telephone number for.
A list of those who have not paid their fee has now been published. Practices are encouraged to check the list to ensure that no employees are named.
The College also wants to remind veterinary surgeons that, although paying the fee is required to remain on the Register, to complete their registration in full they need to confirm they are compliant with the continuing professional development (CPD) requirement and complete the criminal disclosures form. Both of these are required by the Code of Professional Conduct and can be completed on the ‘My Account’ area.
Anyone with queries about completing the registration process should contact the Registration Department on 020 7202 0707 or registration@rcvs.org.uk.
The study, which was led by Robert Hyde MRCVS from the School of Veterinary Medicine and Science at the University of Nottingham, aims to create an automated diagnostic support tool for the diagnosis of herd level mastitis origin, an essential first step of the AHDB mastitis control plan.
Mastitis data from 1,000 herds’ was inputted for several three-month periods. Machine learning algorithms were used to classify herd mastitis origin and compared with expert diagnosis by a specialist vet.
The machine learning algorithms were able to achieve a classification accuracy of 98% for environmental vs contagious mastitis, and 78% accuracy was achieved for the classification of lactation vs dry period environmental mastitis when compared with expert veterinary diagnosis.
Robert said: “Mastitis is a huge problem for dairy farmers, both economically and in welfare terms. In our study we have shown that machine learning algorithms can accurately diagnose the origin of this condition on dairy farms. A diagnostic tool of this kind has great potential in the industry to tackle this condition and to assist veterinary clinicians in making a rapid diagnosis of mastitis origin at herd level in order to promptly implement control measures for an extremely damaging disease in terms of animal health, productivity, welfare and antimicrobial use."
Reference